| Document |
Document Title |
|
WO/2014/169816A1 |
A long acting goserelin sustained release microsphere composition. The microsphere comprises goserelin, at least a lactide/glycolide copolymer, and poloxamer or polyethylene glycol. The sustained release microsphere has a higher bioavail...
|
|
WO/2014/166317A1 |
An external-use medicament for cleaning and care of the ovaries, vagina and vulva, the medicinal raw materials consisting of propolis extract, zedoary oil, and mint leaf filtrate; on the basis of the different properties of each natural ...
|
|
WO/2014/166971A1 |
The invention is directed to a pharmaceutical composition comprising a progesterone receptor antagonist namely (11 β,17β)-17-Hydroxy-11-[4-(methylsulphonyl)phenyl]-17-(penta
fluoroethyl)estra-4,9-dien-3-one at the dosage of about 0.5 t...
|
|
WO/2014/163402A1 |
The present invention relates to a composition which improves the quality of life of women by containing a ginseng berry extract as an active ingredient and, more specifically, to a composition which promotes the general psychological an...
|
|
WO/2014/163520A1 |
The invention relates to medicine and concerns a combined preparation for treating diseases of the rectum and female genitalia (erosion, colpitis, condylomas, cysts, endometriosis, myomas, fibroids, polyps of various localisation, les...
|
|
WO/2014/164771A1 |
The present invention provides for compounds of formula (I) wherein R1, R2, A1, A2, A3, A4, X, and Y have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the tre...
|
|
WO/2014/154168A1 |
Provided are a bicyclic substituted pyrimidine PDE-5 inhibitor prodrug as represented by general formula (I), pharmaceutically acceptable salt or stereoisomer thereof. Also provided are a preparation method of the prodrug compounds, phar...
|
|
WO/2014/139282A1 |
A pharmaceutical composition for preventing and treating cancer of reproductive system and preparation method therefor. The pharmaceutical composition is prepared using one or more of the following as raw material: pinellia tuber, bighea...
|
|
WO/2014/143669A1 |
The present invention relates to the method of treating heavy menstrual bleeding in a subject with or without uterine fibroids and in need of treatment by administering an effective amount of 4-((R)-2-[5-(2-fluoro-3-methoxy-phenyl)-3-(2-...
|
|
WO/2014/140217A1 |
The invention relates to a method for scheduling ovulation in a female subject, which method comprises administering ulipristal acetate (UPA) to the female subject during the follicular phase.
|
|
WO/2014/140075A1 |
This invention relates to 2-Aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)- amides of formula (1) and their use as inhibitors of Cathepsin C, pharmaceutical compositions containing the same, and methods of using the sa...
|
|
WO/2014/140988A1 |
This invention relates to rifaximin for use in the treatment of bacterial vaginal infections. The invention also relates to the use for treating infections characterized by the presence of bacteria that may be clindamycin and/or metronid...
|
|
WO/2014/138953A1 |
Synuclein-gamma (SNCG) inhibitors are useful for inhibiting or treating angiogenesis, endometriosis and/or endometrial lesion growth. They also potentiate efficacy of other hormonal agents in treating angiogenesis, endometriosis and/or e...
|
|
WO/2014/137877A1 |
Provided herein are dry pharmaceutical compositions suitable for transmucosal delivery, comprising dry particles, such as spray-dried particles, that include pharmaceutically active agent nanoparticles, a binder, and a pharmaceutically a...
|
|
WO/2014/127722A1 |
The invention belongs to the technical field of medicines and relates to a nitrogen-heterocyclic-substituted dihydroartemisinin derivative described by formulae I and II and an optical isomer thereof, wherein substituents of X, Y, R, R1,...
|
|
WO/2014/126269A1 |
The present invention relates to a pharmaceutical composition for improving male sexual function and for improving infertility, more specifically relates to a pharmaceutical composition for improving male sexual function and treating inf...
|
|
WO/2014/126362A1 |
The present invention relates to a composition for treating male infertility using a natural substance and, more specifically, to a composition for treating male infertility using a cuscuta seed extract as a natural substance. The use of...
|
|
WO/2014/122670A1 |
The present invention relates to the synthesis and biological evaluation of compound of formula I as spermicidal agents, and its pharmaceutically acceptable acid salt thereof. The invention provides bis(4- substituted-1-piperazinylthioca...
|
|
WO/2014/123305A2 |
|
|
WO/2014/121325A1 |
The present disclosure provides proteins comprising antigen binding sites of antibodies that bind to interleukin-11 (IL-11) receptor alpha (IL-11Rα) and uses thereof, e.g., in therapy.
|
|
WO/2014/119833A1 |
The present invention relates to a composition for use in the prevention or treatment of miscarriage, pre-eclampsia, and an immature fetus, comprising a PECAM-1 activating catalyst as an active ingredient. The PECAM-1 activating catalyst...
|
|
WO/2014/118133A1 |
The present invention relates to new kinase inhibitors of Formula (I) or a stereoisomer, tautomer, racemic, salt, hydrate, or solvate thereof, and more specifically to ROCK inhibitors, compositions, in particular pharmaceuticals, compris...
|
|
WO/2014/120643A1 |
Disclosed herein are methods of inhibiting sperm motility. In some embodiments, a method of inhibiting sperm motility includes contacting a sperm with an effective amount of 3BP, thereby inhibiting sperm motility. Also disclosed herein a...
|
|
WO/2014/119568A1 |
The present invention provides a means for treating cisplatin-resistant cancers. Specifically, the present invention provides a cisplatin-resistant cancer cytotoxic agent or the like, which contains an HMG-CoA reductase inhibitor. The pr...
|
|
WO/2014/114644A1 |
The present invention comprises the use of a therapeutically effective amount of a tungsten (VI) salt with a pharmaceutically or veterinarily acceptable cationic group, or a solvate of said salt, for the preparation of a medicinal produc...
|
|
WO/2014/115113A1 |
Zanthoxylum piperitum (commonly known as Japanese pepper) seeds, including its mature seeds, contain the NMS precursor /V-methylserotonin 5-O-Β-glucoside ("NMS-glucoside") present in sufficient concentration and are metabolized with suf...
|
|
WO/2014/111268A1 |
The invention describes a pharmaceutical association of active ingredients comprising: curcumin, quercetin, chondroitin sulfate and hyaluronic acid, used for the prevention or treatment of bladder, pelvic and urogenital apparatus patholo...
|
|
WO/2014/112641A1 |
A nitric oxide (NO) concentration elevating agent containing glutathione or a salt thereof as an active ingredient, an NO concentration elevating agent containing glutathione or a salt thereof as an active ingredient for preventing or al...
|
|
WO/2014/053418A9 |
The present invention relates to a method for obtaining mesenchymal stem cells (MSCs) from mammalian tissue or body fluid, comprising isolating said MSCs from tissue or body fluid and expanding said isolated MSCs in multiple cultivation ...
|
|
WO/2014/103475A1 |
The purpose of the present invention is to provide a skin-exterior anti-ageing composition for preventing or improving trouble areas upon the exterior of the skin caused by ageing and degradation such as wrinkles, fine lines, blotches, a...
|
|
WO/2014/104171A1 |
The purpose of the present invention is to provide a skin-exterior anti-ageing composition for preventing or improving trouble areas upon the exterior of the skin caused by ageing and degradation such as wrinkles, fine lines, blotches, a...
|
|
WO/2014/015416A9 |
Intravaginal DHEA is used for the treatment of at least one condition selected from the group consisting of female hypoactive sexual desire disorder, female sexual arousal disorder, female orgasm disorder and female sexual interest arous...
|
|
WO/2014/097123A1 |
The present invention relates to a composition comprising lactoferrin and to its use in the prevention of preterm delivery.
|
|
WO/2014/090259A1 |
The invention relates to a composition comprising isoflavones from red clover. The red clover extract has been fermented to obtain a composition comprising aglycone isoflavones. The fermentation is preferably performed by a lactic acid b...
|
|
WO/2014/093486A1 |
A vaginal insert controls pH within a human vagina by use of various probiotics which include lactobacillus reuteri, lactobacillus rhamnosus, lactobacillus casei, lactobacillus plantarum, lactobacillus acidophilus, lactobacillus brevis, ...
|
|
WO/2014/090152A1 |
Provided in the present invention is the use of a nerve growth factor in preparing a drug for treating hypogonadism syndrome in middle-aged and elderly males, which is mainly used to prepare a drug for treating decreasing human testoster...
|
|
WO/2014/089344A2 |
|
|
WO/2014/087218A1 |
The invention relates to GM-CSF for use in a method for the prevention of spontaneous abortion in a subject suffering from recurrent miscarriage, comprising administering to said subject an effective amount of GM-CSF as sole active subst...
|
|
WO/2014/086104A1 |
The present invention relates to the field of drugs, and more particularly to an AMPK activator and an application thereof in preparing drugs for treating and/or preventing diabetes and/or diabetes complications. The present invention pr...
|
|
WO/2014/082724A1 |
The present invention concerns the preparation and the therapeutic use of aqueous solutions of Progesterone or Testosterone, complexed with hydroxypropyl-3-cyclodextrin (HPβCD) that are suitable for oral administration. The solutions ar...
|
|
WO/2014/084964A1 |
Provided are compositions and methods for use in prophylaxis of puerperal metritis and improving reproductive function of ruminants. The methods and compositions are for subcutaneous administration and are provided as veterinary composit...
|
|
WO/2014/082773A1 |
Composition containing a microorganism, preferably an Archaea, expressing a TMA methyltransferase and a TMA methyl group acceptor corrinoid protein, capable of metabolizing trimethylamine (TMA) in the presence of hydrogen in a human cavi...
|
|
WO/2014/081598A1 |
The technology described herein relates to KIM-1 and the diagnosis, prognosis, and treatment of endometrial diseases and disorders.
|
|
WO/2014/079384A1 |
Disclosed are gonadotropin fusion proteins or thyroid stimulating hormone fusion proteins, preparation methods and applications thereof. The beta subunit of gonadotropin or thyroid stimulating hormone fuses to Fc fragment directly or ind...
|
|
WO/2014/075387A1 |
Provided are a compound as represented by formula I, or pharmaceutically acceptable salt, solvate, precursor drug, stereoisomer, tautomer, polymorph or metabolite thereof, pharmaceutical composition containing same, and uses thereof in t...
|
|
WO/2014/072647A1 |
The invention relates to a co-micronisation product comprising: an active principle selected from the group containing selective progesterone-receptor modulators, metabolites thereof and mixtures of same and an N-vinyl-2-pyrrolidone-base...
|
|
WO/2014/072350A1 |
The invention relates to a new use of NAC in IVF, in a human or mammalian animal patient. In addition an effective dose regimen of NAC in IVF is proposed.
|
|
WO/2014/072646A1 |
The invention relates to a co-micronisation product comprising: an active principle selected from the group containing ulipristal acetate, a metabolite thereof and mixtures of same, and a pharmaceutically acceptable solid surfactant. The...
|
|
WO/2014/072230A1 |
Disclosed are vaginal compositions containing a tamarind seed extract for use in the treatment of atrophic vaginitis in post-menopausal women.
|
|
WO/2014/072245A1 |
Based on specific experimental studies the invention relates to an optimized levonorgestrel-only-composition for improved continuous oral contraception with consequences for suitable pharmaceutical preparations for the same purpose and w...
|
